Appendix 4D and Interim Financial Report
Filed with ASX · · 26 pages · English
This half-year financial report is to be read in conjunction with the financial report for the year ended 30 June 2025. Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of precision diagnostics and bioanalytical services. The Company specialises in the area of proteomics – the industr
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- Quarterly Activities/Appendix 4C Cash Flow Report
- Canadian patent secured for PromarkerEso test for EAC
- Appointment of CEO and Managing Director
- Proteomics US lab CAP accredited - extends precision Dx lab
- US patent secured for PromarkerEso diagnostic test for EAC
Later from Proteomics International Laboratories
- Restructure, Executive Appointment and Board Update
- Proteomics Strategic Plan
- US patent secured for PromarkerEndo
- Proteomics signs national distribution deal with Healius
- Australian patent for PromarkerEndo
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories